• 20 January 2020

    MAPS secures approval to expand MDMA therapy access for PTSD in US

    Multidisciplinary Association for Psychedelic Studies (MAPS) has received US Food and Drug Administration (FDA) approval to expand access to 3,4-methylenedioxy-methamphetamine (MDMA)-based psychotherapy for post-traumatic stress disorder (PTSD).

Close
Close
Close

Go Top